Prophylaxis of chronic kidney disease after liver transplantation - experience from west China

Figure 2 Calcineurin inhibitor trough concentrations between different groups. We compared the mean trough concentrations of tacrolimus (TAC) and cyclosporine A (CSA) at different time points between patients with and without chronic kidney disease (CKD) (A and B), between patients combined mycophenolate mofetil (MMF) use and no use (C and D). A: Trough concentrations of TAC grouped by CKD and non-CKD at different time points. Apart from 5 years after liver transplantation (LT), the CKD people had higher TAC trough concentrations than non-CKD people with statistical significance; B: Trough concentrations of CSA grouped by CKD and non-CKD at different time points. The CKD people had higher CSA trough concentrations than non-CKD people with statistical significance in 1, 2, 3, 4 years after LT; C and D: Trough concentrations of TAC (C) and CSA (D) grouped by combination with and without MMF at different time points. Patients with MMF combination had a lower calcineurin inhibitor trough concentrations but most without statistical significance. NS: Not significant.